People_

Professor Sandra O'Toole

Professor
School of Medical Sciences
Faculty of Medicine and Health

Phone

95157182

Fax

951558405

sandra.otoole@sydney.edu.au

After graduating from Medicine from UNSW with the University Medal in 1997 and finishing my specialist training as a pathologist in 2003, I spent 2 years as a postdoctoral fellow at Johns Hopkins Hospital, completing my PhD in 2008 at the Garvan Institute of Medical Research. I currently divide my time between Royal Prince Alfred Hospital (as Staff Specialist in the Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and Head of Diagnostic Molecular Oncology) and the Garvan Institute of Medical Research as Head of Translational Breast Cancer Research.

Research interests

My research interest focuses on markers of breast cancer recurrence or progression in human tissues. I also have an interest in developmental pathways as potential novel therapeutic targets in breast cancer.

I am passionate about the translation of research into clinical practice, reflected in my clinical role as a molecular pathologist, integrating cutting edge technologies into the hospital setting. Much of my recent research concentrates on the application of molecular pathology to guide patient diagnosis and treatment selection.

Teaching and supervision

I currently supervise a number of honours, masters and a PhD student.

Themes

Cancer

Keywords

Breast cancer, Lung cancer, Melanoma and skin cancer

International links

United States

(McGill University Canada) Prof William Muller

United States

(University of Ohio) Prof Tsonwin HaiProfessor College of Medicine

Publications

By Type

Expand all

Journals

Wahi, K., Harvey, K., O'Toole, S., Guan, Y., Holst, J., Freidman, N., Wang, Q., Devadason, M., Quek, L., Pang, A., Larance, M., et al (2024). Macropinocytosis mediates resistance to loss of glutamine transport in triple-negative breast cancer. EMBO Journal, Online(17 October 2024), 1-26. [More Information]
Lambouras, M., Roelofs, C., Pereira, M., Gruber, E., Vieusseux, J., Lanteri, P., Johnstone, C., Muntz, F., O'Toole, S., Ooms, L., et al (2023). Functional and Phenotypic Characterisations of Common Syngeneic Tumour Cell Lines as Estrogen Receptor-Positive Breast Cancer Models. International Journal of Molecular Sciences, 24(6), 5666. [More Information]
McKenzie, C., Karim, R., Kench, J., Klebe, S., Kramer, N., Kumarasinghe, M., Maclean, F., Morey, A., Nguyen, M., O'Toole, S., Gupta, R., Salisbury, E., Scolyer, R., Cooper, W., Anderson, L., Chen, V., et al (2023). Looking beyond workforce parity: addressing gender inequity in pathology. Pathology, 55(6), 760-771. [More Information]
Mulholland, B., Hofstee, P., Millar, E., Bliuc, D., OToole, S., Forwood, M., Mcdonald, M. (2023). MCP-1 expression in breast cancer and its association with distant relapse. Cancer Medicine, 12(15), 16221-16230. [More Information]
Lee, K., Seah, J., O'Toole, S., Warrier, S. (2023). Xanthogranulomatous inflammation and spindle cell proliferation in response to silicone breast implant leakage. BMJ Case Reports, 16(1). [More Information]
Hort, A., O'Toole, S., Yunaev, M. (2022). An unusual case of invasive lobular carcinoma with abundant extracellular mucin. Pathology, 54(1), 138-140. [More Information]
Scolyer, R., Atkinson, V., Gyorki, D., Lambie, D., O'Toole, S., Saw, R., Amanuel, B., Angel, C., Button-Sloan, A., Carlino, M., Ch'ng, S., Daneshvar, D., Esteves Domingues Pires da Silva, I., Ferguson, P., Gill, A., Gupta, R., Hong, A., Howle, J., Jackett, L., Lee, C., et al (2022). BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 54(1), 6-19. [More Information]
Potter, A., Colebatch, A., Rawson, R., Ferguson, P., Cooper, W., Gupta, R., O'Toole, S., Saw, R., Ch'ng, S., Menzies, A., Long, G., Scolyer, R. (2022). Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. Pathology, 54(5), 526-532. [More Information]
Cserni, G., Brogi, E., Cody, H., Deb, R., Farshid, G., OToole, S., Provenzano, E., Quinn, C., Sahin, A., Schmitt, F., et al (2022). Reporting of Surgically Removed Lymph Nodes for Breast Tumors: Recommendations From the International Collaboration on Cancer Reporting. Archives of Pathology & Laboratory Medicine, 146(11), 1308-1318. [More Information]
Fielder, T., Butler, J., Tierney, G., Holmes, M., Lam, K., Satgunaseelan, L., Colebatch, A., Mahar, A., Gupta, R., O'Toole, S., Cooper, W. (2022). ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical expression of ROS1. Pathology, 54(4), 399-403. [More Information]
Papanicolaou, M., Parker, A., Yam, M., Filipe, E., Wu, S., Chitty, J., Wyllie, K., Tran, E., Mok, E., Nadalini, A., Oliver, B., Parker, B., et al (2022). Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis. Nature Communications, 13(1). [More Information]
Wu, S., Roden, D., Al-Eryani, G., Bartonicek, N., Harvey, K., Cazet, A., Chan, C., Junankar, S., Hui, M., Millar, E., Horvath, L., Wilmott, J., Quek, C., Long, G., Scolyer, R., et al (2021). Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. Genome Medicine, 13(1), 81. [More Information]
Paver, E., Cooper, W., Colebatch, A., Ferguson, P., Hill, S., Lum, T., Shin, J., O'Toole, S., Anderson, L., Scolyer, R., Gupta, R. (2021). Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology, 53(2), 141-156. [More Information]
Paver, E., O'Toole, S., Cheng, X., Mahar, A., Cooper, W. (2021). Updates in the molecular pathology of non-small cell lung cancer. Seminars in Diagnostic Pathology, 38(5), 54-61. [More Information]
Jankovic-Karasoulos, T., Bianco-Miotto, T., Butler, M., Butler, L., McNeil, C., O’Toole, S., Millar, E., Sakko, A., Ruiz, A., Birrell, S., et al (2020). Elevated levels of tumour apolipoprotein D independently predict poor outcome in breast cancer patients. Histopathology, 76(7), 976-987. [More Information]
Kalaw, E., Lim, M., Kutasovic, J., Sokolova, A., Taege, L., Johnstone, K., Bennett, J., Saunus, J., Niland, C., Ferguson, K., Pathmanathan, N., et al (2020). Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. British Journal of Cancer, 123(11), 1665-1672. [More Information]
Millar, E., Browne, L., Slapetova, I., Shang, F., Ren, Y., Bradshaw, R., Brauer, H., O'Toole, S., Beretov, J., Whan, R., et al (2020). Tils immunophenotype in breast cancer predicts local failure and overall survival: Analysis in a large radiotherapy trial with long-term follow-up. Cancers, 12(9), 1-15. [More Information]
Smith, H., Hirukawa, A., Sanguin-Gendreau, V., Nandi, I., Dufour, C., Zuo, D., Tandoc, K., Leibovitch, M., Singh, S., Rennhack, J., Beith, J., O'Toole, S., et al (2019). An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. Nature Communications, 10(1), 1-19. [More Information]
Luk, P., Selinger, C., Cooper, W., Mahar, A., Palme, C., O'Toole, S., Clark, J., Gupta, R. (2019). Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms. Head and Neck Pathology, 13(3), 397-414. [More Information]
McCabe, M., Gauthier, M., Chan, C., Thompson, T., De Sousa, S., Puttick, C., Grady, J., Gayevskiy, V., Tao, J., Ying, K., Kohonen-Corish, M., O'Toole, S., Clark, J., Gupta, R., et al (2019). Development and validation of a targeted gene sequencing panel for application to disparate cancers. Scientific Reports, 9(1), 1-16. [More Information]
Heyer, E., Deveson, I., Wooi, D., Selinger, C., Lyons, R., Hayes, V., O'Toole, S., Ballinger, M., Gill, D., Thomas, D., et al (2019). Diagnosis of fusion genes using targeted RNA sequencing. Nature Communications, 10(1), 1-12. [More Information]
Vargas, A., Selinger, C., Satgunaseelan, L., Cooper, W., Gupta, R., Stalley, P., Brown, W., Soper, J., Schatz, J., Boyle, R., Tattersall, M., Bhadri, V., Scolyer, R., Karim, R., McCarthy, S., O'Toole, S., et al (2019). FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. Asia-Pacific Journal of Clinical Oncology, 15(1), 38-47. [More Information]
Strach, M., Prasanna, T., Kirova, Y., Alran, S., O'Toole, S., Beith, J., Poortmans, P., McNeil, C., Carroll, S. (2019). Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery. Critical Reviews in Oncology / Hematology (online), 134, 10-21. [More Information]
Brockwell, N., Rautela, J., Owen, K., Gearing, L., Deb, S., Harvey, K., Spurling, A., Zanker, D., Chan, C., Cumming, H., O'Toole, S., et al (2019). Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. n p j Precision Oncology, 3(1). [More Information]
Zilberg, C., Lee, M., Yu, B., Ashford, B., Kraitsek, S., Ranson, M., Shannon, K., Cowley, M., Iyer, N., Palme, C., Ch'ng, S., Low, T., O'Toole, S., Clark, J., Gupta, R. (2018). Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma. Modern Pathology, 31(2), 275-287. [More Information]
Duivenvoorden, H., Spurling, A., O'Toole, S., Parker, B. (2018). Discriminating the earliest stages of mammary carcinoma using myoepithelial and proliferative markers. PloS One, 13(7), 1-12. [More Information]
Gupta, R., Cooper, W., Selinger, C., Mahar, A., Anderson, L., Buckland, M., O'Toole, S. (2018). Fluorescent In Situ Hybridization in Surgical Pathology Practice. Advances in Anatomic Pathology, 25(4), 223-237. [More Information]
Rogers, S., McCloy, R., Parker, B., Gallego-Ortega, D., Law, A., Chin, V., Conway, J., Fey, D., Millar, E., O'Toole, S., Cesare, A., James, D., Burgess, A., et al (2018). MASTL overexpression promotes chromosome instability and metastasis in breast cancer. Oncogene, 37(33), 4518-4533. [More Information]
Pajic, M., Froio, D., Daly, S., Doculara, L., Millar, E., Graham, P., Drury, A., Steinmann, A., de Bock, C., O'Toole, S., Gee, H., et al (2018). miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense. Cancer Research, 78(2), 501-515. [More Information]
Cazet, A., Hui, M., Elsworth, B., Wu, S., Roden, D., Chan, C., Skhinas, J., Collot, R., O'Toole, S., et al (2018). Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nature Communications, 9(1), 2897. [More Information]
Ricciardelli, C., Bianco-Miotto, T., Jindal, S., Butler, L., Leung, S., McNeil, C., O'Toole, S., Ebrahimie, E., Millar, E., et al (2018). The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. Clinical Cancer Research, 24(10), 2328-2340. [More Information]
Zardavas, D., te Marvelde, L., Milne, R., Fumagalli, D., Fountzilas, G., Kotoula, V., Razis, E., Papaxoinis, G., Joensuu, H., O’Toole, S., et al (2018). Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. Journal of Clinical Oncology, 36(10), 981-990. [More Information]
Law, A., Yin, J., Castillo, L., Young, A., Piggin, C., Rogers, S., Caldon, C., Burgess, A., Millar, E., O’Toole, S., et al (2017). Andy's Algorithms: New automated digital image analysis pipelines for FIJI. Scientific Reports, 7(1), 1-11. [More Information]
Pang, J., Savas, P., Fellowes, A., Mir Arnau, G., Kader, T., Vedururu, R., Hewitt, C., Takano, E., Byrne, D., Lee, C., O'Toole, S., et al (2017). Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. Modern Pathology, 30(7), 952-963. [More Information]
Barnet, M., O'Toole, S., Horvath, L., Selinger, C., Yu, B., Ng, C., Boyer, M., Cooper, W., Kao, S. (2017). EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 12(3), 585-590. [More Information]
Pang, J., Molania, R., Chand, A., Knower, K., Takano, E., Byrne, D., Mikeska, T., Millar, E., Lee, C., O'Toole, S., et al (2017). LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness. Oncotarget, 8(48), 83626-83636. [More Information]
Harris, G., O'Toole, S., George, P., Browett, P., Print, C. (2017). Massive parallel sequencing of solid tumours - challenges and opportunities for pathologists. Histopathology, 70, 123-133. [More Information]
Duivenvoorden, H., Rautela, J., Edgington-Mitchell, L., Spurling, A., Greening, D., Nowell, C., Molloy, T., Robbins, E., Brockwell, N., Lee, C., O'Toole, S., et al (2017). Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion. Journal of Pathology, 243(4), 496-509. [More Information]
Selinger, C., Li, B., Pavlakis, N., Links, M., Gill, A., Lee, A., Clarke, S., Tran, T., Lum, T., Yip, P., Horvath, L., Yu, B., O'Toole, S., Cooper, W., et al (2017). Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. Histopathology, 70(3), 402-411. [More Information]
Khoo, T., Yu, B., Smith, J., Clarke, A., Luk, P., Selinger, C., Mahon, K., Kraitsek, S., Palme, C., Boyer, M., O'Toole, S., Clark, J., Gupta, R., et al (2017). Somatic mutations in salivary duct carcinoma and potential therapeutic targets. Oncotarget, 8(44), 75893-75903. [More Information]
Coulson, R., Liew, S., Connelly, A., Yee, N., Deb, S., Kumar, B., Vargas, A., O'Toole, S., Parslow, A., Poh, A., et al (2017). The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget, 8(12), 18640-18656. [More Information]
Tran, T., Selinger, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2016). Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases. Clinical Lung Cancer, 17(1), 30-38. [More Information]
van Geldermalsen, M., Wang, Q., Nagarajah, R., Marshall, A., Thoeng, A., Gao, D., Ritchie, W., Feng, Y., Bailey, C., Deng, N., Beith, J., O'Toole, S., Rasko, J., Holst, J., et al (2016). ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene, 35(24), 3201-3208. [More Information]
Vargas, A., Selinger, C., Satgunaseelan, L., Cooper, W., Gupta, R., Stalley, P., Brown, W., Soper, J., Schatz, J., Boyle, R., Tattersall, M., Bhadri, V., Scolyer, R., Karim, R., McCarthy, S., O'Toole, S., et al (2016). Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. Histopathology, 69(6), 1000-1011. [More Information]
Kakavand, H., Walker, E., Lum, T., Wilmott, J., Selinger, C., Smith, E., Saw, R., Yu, B., Cooper, W., Long, G., O'Toole, S., Scolyer, R. (2016). BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology, 69(4), 680-686. [More Information]
Ryu, S., Ho, K., O'Toole, S., Green, A., Kim, H. (2016). Case report of male breast cancer detected on magnetic resonance imaging. Journal of Medical Imaging and Radiation Oncology, 61(3), 369-371. [More Information]
Luk, P., Wykes, J., Selinger, C., Ekmejian, R., Tay, J., Gao, K., Eviston, T., Lum, T., O'Toole, S., Clark, J., Gupta, R. (2016). Diagnostic and prognostic utility of Mastermind-like 2 (MAML2) gene rearrangement detection by fluorescent in situ hybridization (FISH) in mucoepidermoid carcinoma of the salivary glands. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 121(5), 530-541. [More Information]
Russell, P., Van Der Griend, R., Anderson, L., Yu, B., O'Toole, S., Simcock, B. (2016). Evidence for lymphatic pathogenesis of endosalpingiosis. Pathology, 48(1), 72-76. [More Information]
Reagh, J., Eckstein, R., Selinger, C., Evans, J., O'Toole, S., Gill, A. (2016). Liposarcoma masquerading as an inflammatory pseudotumor: a case report. Journal of Medical Case Reports, 10(1), 1-3. [More Information]
Young, A., Law, A., Castillo, L., Chong, S., Cullen, H., Koehler, M., Herzog, S., Brummer, T., Lee, E., O'Toole, S., et al (2016). MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib. Breast Cancer Research, 18(1), 1-15. [More Information]
Beckers, R., Selinger, C., Vilain, R., Madore, J., Wilmott, J., Harvey, K., Holliday, A., Cooper, C., Robbins, E., Gillett, D., Kennedy, C., Gluch, L., Carmalt, H., Warrier, S., Gee, H., Chan, C., McLean, A., Walker, E., McNeil, C., Beith, J., Scolyer, R., O'Toole, S., et al (2016). Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology, 69(1), 25-34. [More Information]
Luk, P., Weston, J., Yu, B., Selinger, C., Ekmejian, R., Eviston, T., Lum, T., Gao, K., Boyer, M., O'Toole, S., Clark, J., Gupta, R. (2016). Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations. Head and Neck, 38(Suppl 1), e1838-e1847. [More Information]
Denkert, C., Wienert, S., Poterie, A., Loibl, S., Budczies, J., Badve, S., Bago-Horvath, Z., Bane, A., Bedri, S., O'Toole, S., et al (2016). Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 29(10), 1155-1164. [More Information]
Lyle, M., Haydu, L., Menzies, A., Thompson, J., Saw, R., Spillane, A., Kefford, R., Mann, G., Cooper, W., Yu, B., Scolyer, R., O'Toole, S., Long, G. (2016). The molecular profile of metastatic melanoma in Australia. Pathology, 48(2), 188-193. [More Information]
O'Toole, S. (2016). What do I need to know about somatic mutation testing as a tissue pathologist - A survival guide? Advances in Anatomic Pathology, 48(S1), S9-S10. [More Information]
Chou, A., Fraser, S., Toon, C., Clarkson, A., Sioson, L., Farzin, M., Cussigh, C., Aniss, A., O'Neill, C., Watson, N., Clifton-Bligh, R., Learoyd, D., Robinson, B., Delbridge, L., Sidhu, S., O'Toole, S., Sywak, M., Gill, A., et al (2015). A Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 39(5), 652-659. [More Information]
Luk, P., Yu, B., Ng, C., Mercorella, B., Selinger, C., Lum, T., Kao, S., O'Toole, S., Cooper, W. (2015). BRAF mutations in non-small cell lung cancer. Translational Lung Cancer Research, 4(2), 142-148. [More Information]
Loh, S., Cooper, C., Selinger, C., Barnes, E., Chan, C., Carmalt, H., West, R., Gluch, L., Beith, J., Caldon, C., O'Toole, S. (2015). Cell cycle marker expression in benign and malignant intraductal papillary lesions of the breast. Journal of Clinical Pathology, 68(3), 187-191. [More Information]
Gallego-Ortega, D., Ledger, A., Roden, D., Law, A., Magenau, A., Kikhtyak, Z., Cho, C., Allerdice, S., Lee, H., Valdes-Mora, F., Naylor, M., O'Toole, S., et al (2015). ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells. PLoS Biology, 13(12), 1-27. [More Information]
Li, B., Lee, A., O'Toole, S., Cooper, W., Yu, B., Chaft, J., Arcila, M., Kris, M., Pavlakis, N. (2015). HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. Lung Cancer, 90(3), 617-619. [More Information]
Junankar, S., Baker, L., Roden, D., Nair, R., Elsworh, B., Gallego-Ortega, D., Lacaze, P., Cazet, A., Nikolic, I., Teo, W., Naylor, M., O'Toole, S., et al (2015). ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype. Nature Communications, 6, 1-12. [More Information]
Luk, P., Selinger, C., Eviston, T., Lum, T., Yu, B., O'Toole, S., Clark, J., Gupta, R. (2015). Mammary analogue secretory carcinoma: an evaluation of its clinicopathological and genetic characteristics. Pathology, 47(7), 659-666. [More Information]
Phua, Y., Nguyen, A., Roden, D., Elsworth, B., Deng, N., Nikolic, I., Yang, J., McFarland, A., Russell, R., Kaplan, W., O'Toole, S., James, D., et al (2015). MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene. Breast Cancer Research, 17(1), 1-18. [More Information]
Gee, H., Buffa, F., Harris, A., Toohey, J., Carroll, S., Cooper, C., Beith, J., McNeil, C., Carmalt, H., Mak, C., Kennedy, C., O'Toole, S., et al (2015). MicroRNA-Related DNA repair/ cell-cycle genes independently associated with relapse after radiation therapy for early breast cancer. International Journal of Radiation Oncology Biology Physics, 93(5), 1104-1114. [More Information]
Cooper, W., Tran, T., Vilain, R., Madore, J., Selinger, C., Kohonen-Corish, M., Yip, P., Yu, B., O'Toole, S., McCaughan, B., Horvath, L., Kao, S., Boyer, M., Scolyer, R., et al (2015). PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 89(2), 181-188. [More Information]
Warrier, S., Hwang, S., Gibbings, K., Carmalt, H., O'Toole, S. (2015). Phyllodes tumour with heterologous sarcomatous differentiation: Case series with literature review. International Journal of Surgery Case Reports, 11, 91-94. [More Information]
Yu, B., O'Toole, S., Trent, R. (2015). Somatic DNA mutation analysis in targeted therapy of solid tumours. Translational Pediatrics, 4(2), 125-138. [More Information]
Wang, S., Yu, B., Ng, C., Mercorella, B., Selinger, C., O'Toole, S., Cooper, W. (2015). The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. Translational Lung Cancer Research, 4(2), 119-125. [More Information]
Gibbings, K., Warrier, S., Hwang, S., Rice, M., O'Toole, S., Carmalt, H. (2014). A giant phyllodes tumour with sepsis. ANZ Journal of Surgery, 84(11), 886-887. [More Information]
Tran, T., Selinger, C., Yu, B., Ng, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2014). Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer. Journal of Clinical Pathology, 67(11), 985-991. [More Information]
Nair, R., Roden, D., Teo, W., McFarland, A., Junankar, S., Ye, S., Nguyen, A., Yang, J., Nicolic, I., Hui, M., Armstrong, N., Naylor, M., O'Toole, S., et al (2014). c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene, 33(30), 3992-4002. [More Information]
Kakavand, H., Crainic, O., Lum, T., O'Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193-198. [More Information]
Carlino, M., Haydu, L., Kakavand, H., Menzies, A., Hamilton, A., Yu, B., Ng, C., Cooper, W., Thompson, J., Kefford, R., O'Toole, S., Scolyer, R., Long, G. (2014). Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 111(2), 292-299. [More Information]
Houang, M., Sioson, L., Clarkson, A., Watson, N., Mahtab, F., Toon, C., Raut, A., O'Toole, S., Cooper, W., Pavlakis, N., Gill, A., et al (2014). EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology, 46(6), 501-508. [More Information]
Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
Pang, J., Deb, S., Takano, E., Byrne, D., Jene, N., Boulghourjian, A., Holliday, A., Millar, E., Lee, C., O'Toole, S., et al (2014). Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features. Breast Cancer Research, 16(1), 1-11. [More Information]
O'Toole, S., Yu, B., Cooper, W. (2014). Molecular Diagnosis in Cytology and Its Place in the New Classification: A Practical Guide. The Journal of OncoPathology, 2(1), 63-73. [More Information]
Cooper, W., Fox, S., O'Toole, S., Morey, A., Frances, G., Pavlakis, N., O'Brien, K., Dettrick, A., Leong, T., Rathi, V., et al (2014). National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 10(S 2), 11-17. [More Information]
Houang, M., Toon, C., Clarkson, A., Sioson, L., Watson, N., Farzin, M., Selinger, C., Chou, A., Morey, A., Cooper, W., O'Toole, S., Gill, A. (2014). Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer. Pathology, 46(5), 383-388. [More Information]
Nguyen, N., Hampartzoumian, T., Cameron, B., Palmer, C., O'Toole, S., Post, J., Zekry, A., Lloyd, A. (2014). Regulation of T cell recruitment and inflammation in the human immunodeficiency virus/hepatitis C virus coinfected liver. Journal of Gastroenterology and Hepatology, 29(7), 1535-1543. [More Information]
Schade, B., Lesurf, R., Sanguin-Gendreau, V., Bui, T., Deblois, G., O'Toole, S., Millar, E., Zardawi, S., Lopez-Knowles, E., Sutherland, R., et al (2013). B-Catenin Signaling is a Critical Event in ErbB2-Mediated Mammary Tumor Progression. Cancer Research, 73(14), 4474-4487. [More Information]
Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma. European Journal of Cancer, 49(5), 1073-1079. [More Information]
Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma â€“ Response. European Journal of Cancer, 49(7), 1797-1798. [More Information]
O'Toole, S., Rakha, E., Ellis, I., Tan, P. (2013). Breast pathology today: morphology and molecules. Journal of Clinical Pathology, 66(6), 457. [More Information]
Cooper, C., O'Toole, S., Kench, J. (2013). Classification, morphology and molecular pathology of premalignant lesions of the pancreas. Pathology, 45(3), 286-304. [More Information]
Cooper, W., Yu, B., Yip, P., Ng, C., Lum, T., Farzin, M., Trent, R., Mercorella, B., Clarkson, A., Kohonen-Corish, M., Horvath, L., Kench, J., McCaughan, B., Gill, A., O'Toole, S. (2013). EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. Journal of Clinical Pathology, 66(9), 744-748. [More Information]
Tran, T., Selinger, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2013). Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer, 81(3), 462-467. [More Information]
Browne, B., Hochgrafe, F., Wu, J., Millar, E., Barraclough, J., Stone, A., McCloy, R., Lee, C., Roberts, C., Ali, N., O'Toole, S., et al (2013). Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. FEBS Journal, 280(21), 5237-5257. [More Information]
Cooper, C., Karim, R., Selinger, C., Carmalt, H., Lee, C., O'Toole, S. (2013). Molecular alterations in metaplastic breast carcinoma. Journal of Clinical Pathology, 66(6), 522-528. [More Information]
Cooper, W., Lam, D., O'Toole, S., Minna, J. (2013). Molecular biology of lung cancer. Journal of Thoracic Disease, 5(S5), S479-S490. [More Information]
Cooper, W., O'Toole, S. (2013). Molecular Pathology in lung Cancer. Cancer Forum, 37(2), 1-7.
Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C., Kennedy, C., Kohonen-Corish, M., McCaughan, B., Trent, R., Boyer, M., Kench, J., Horvath, L., O'Toole, S. (2013). Patterns of DNA mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology, 8(4), 408-414. [More Information]
Saunderson, R., Garsia, R., Headley, A., McCaughan, G., O'Toole, S., Strasser, S. (2013). Pentoxifylline-induced drug rash with eosinophilia and systemic symptoms (DRESS) in a patient with caffeine intolerance. Journal of Dermatological Case Reports, 7(3), 77-81. [More Information]
Karim, R., O'Toole, S., Scolyer, R., Cooper, C., Chan, B., Selinger, C., Yu, B., Carmalt, H., Mak, C., Tse, G., Lee, C., et al (2013). Recent insights into the molecular pathogenesis of mammary phyllodes tumours. Journal of Clinical Pathology, 66(6), 496-505. [More Information]
Shields, B., Wiede, F., Gurzov, E., Wee, K., Hauser, C., Zhu, H., Molloy, T., O'Toole, S., Daly, R., Sutherland, R., et al (2013). TCPTP Regulates SFK and STAT3 Signaling and Is Lost in Triple-Negative Breast Cancers. Molecular and Cellular Biology, 33(3), 557-570. [More Information]
Selinger, C., Rogers, T., Russell, P., O'Toole, S., Yip, P., Wright, G., Wainer, Z., Horvath, L., Boyer, M., McCaughan, B., et al (2013). Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology, 26(12), 1545-1553. [More Information]
Hui, M., Cazet, A., Nair, R., Watkins, D., O'Toole, S., Swarbrick, A. (2013). The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Research, 15(2), 1-14. [More Information]
O'Toole, S., Beith, J., Millar, E., West, R., McLean, A., Cazet, A., Swarbrick, A., Oakes, S. (2013). Therapeutic targets in triple negative breast cancer. Journal of Clinical Pathology, 66(6), 530-542. [More Information]
Coates, A., Millar, E., O'Toole, S., Molloy, T., Viale, G., Goldhirsch, A., Regan, M., Gelber, R., Sun, Z., Castiglione-Gertsch, M., et al (2012). Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Research, 14(6), 1-12. [More Information]
Xu, H., Yan, M., Patra, J., Natrajan, R., Yan, Y., Swagemakers, S., Tomaszewski, J., Verschoor, S., Millar, E., van der Spek, P., O'Toole, S., McNeil, C., et al (2011). Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Research, 13(1), R9-1-R9-36. [More Information]
O'Toole, S., Machalek, D., Shearer, R., Millar, E., Nair, R., Schofield, P., McLeod, D., Cooper, C., McNeil, C., McFarland, A., et al (2011). Hedgehog Overexpression Is Associated with Stromal Interactions and Predicts for Poor Outcome in Breast Cancer. Cancer Research, 71(11), 4002-4014. [More Information]
Roberts, C., Millar, E., O'Toole, S., McNeil, C., Lehrbach, G., Pinese, M., Tobelmann, P., McCloy, R., Musgrove, E., Sutherland, R., et al (2011). Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene, 30(28), 3186-3197. [More Information]
O'Toole, S., Selinger, C., Millar, E., Lum, T., Beith, J. (2011). Molecular assays in breast cancer pathology. Pathology, 43(2), 116-127. [More Information]
Millar, E., Graham, P., McNeil, C., Browne, L., O'Toole, S., Boulghourjian, A., Kearsley, J., Papadatos, G., Delaney, G., Fox, C., et al (2011). Prediction of outcome of early ER + breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. British Journal of Cancer, 105(2), 272-280. [More Information]
Colvin, E., Susanto, J., Kench, J., Ong, V., Mawson, A., Pinese, M., Chang, D., Rooman, I., O'Toole, S., Segara, D., et al (2011). Retinoid signaling in pancreatic cancer, injury and regeneration. PloS One, 6(12), e29075 - 1-e29075 - 10. [More Information]
Chan, P., MÃ¶ller, A., Liu, M., Sceneay, J., Wong, C., Waddell, N., Huang, K., Dobrovic, A., Millar, E., O'Toole, S., et al (2011). The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. Breast Cancer Research, 13(1), 1-10. [More Information]
Cooper, W., O'Toole, S., Boyer, M., Horvath, L., Mahar, A. (2011). What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 43(2), 103-115. [More Information]
Lopez-Knowles, E., Zardawi, S., McNeil, C., Millar, E., Crea, P., Musgrove, E., Sutherland, R., O'Toole, S. (2010). Cytoplasmic Localization of beta-Catenin is a Marker of Poor Outcome in Breast Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 19(1), 301-309. [More Information]
Zardawi, S., Zardawi, I., McNeil, C., Millar, E., McLeod, D., Morey, A., Crea, P., Murphy, N., Pinese, M., Lopez-Knowles, E., Hamilton, A., Spillane, A., Lee, C., et al (2010). High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology, 56(3), 286-296. [More Information]
Murphy, N., Biankin, A., Millar, E., McNeil, C., O'Toole, S., Segara, D., Crea, P., Olayioye, M., Lee, C., Fox, S., et al (2010). Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. International Journal of Cancer, 126(6), 1445-1453. [More Information]
Fleuren, E., O'Toole, S., Millar, E., McNeil, C., Lopez-Knowles, E., Boulghourjian, A., Croucher, D., Schramek, D., Brummer, T., Penninger, J., et al (2010). Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development. International Journal of Cancer, 127(6), 1486-92. [More Information]
Lopez-Knowles, E., O'Toole, S., McNeil, C., Millar, E., Qiu, M., Crea, P., Daly, R., Musgrove, E., Sutherland, R. (2010). PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. International Journal of Cancer, 126(5), 1121-1131. [More Information]
Nair, R., Junankar, S., O'Toole, S., Shah, J., Borowsky, A., Bishop, J., Swarbrick, A. (2010). Redefining the expression and function of the inhibitor of differentiation 1 in mammary gland development. PloS One, 5(8), 1-7. [More Information]
Palmer, C., Corpuz, T., Marianne, G., O'Toole, S., Yan, K., Bu, Y., Jorgenson, J., Talbot, M., Loi, K., Lloyd, A., et al (2010). The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis c infection. Gut, 59(3), 397-404. [More Information]
Hochgrafe, F., Zhang, L., O'Toole, S., Browne, B., Pinese, M., Cubas, A., Lehrbach, G., Lehrbach, D., Rickwood, D., Boulghourjian, A. (2010). Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells. Cancer Research, 70(22), 9391-9401. [More Information]
Millar, E., Anderson, L., McNeil, C., O'Toole, S., Pinese, M., Crea, P., Morey, A., Biankin, A., Henshall, S., Musgrove, E., et al (2009). BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. British Journal of Cancer, 100(1), 123-133. [More Information]
Millar, E., Dean, J., McNeil, C., O'Toole, S., Henshall, S., Lin, J., Quong, A., Comstock, C., Witkiewicz, A., Musgrove, E., et al (2009). Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene, 28(15), 1812-1820. [More Information]
Zhang, J., O'Toole, S., Sutherland, R., Musgrove, E. (2009). Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histology and histopathology, 24(3), 385-398. [More Information]
Kitzing, B., O'Toole, S., Waugh, A., Clayton, J., McGill, N., Allman, K. (2009). Hepatobiliary scintigraphy in vasculitis of the gallbladder as a manifestation of polyarteritis nodosa: a case report. Cases Journal, 2, 9300. [More Information]
Millar, E., Graham, P., O'Toole, S., McNeil, C., Browne, L., Morey, A., Eggleton, S., Beretov, J., Theocharous, C., Capp, A. (2009). Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. Journal of Clinical Oncology, 27(28), 4701-4708. [More Information]
O'Toole, S., Swarbrick, A., Sutherland, R. (2009). The Hedgehog signalling pathway as a therapeutic target in early breast cancer development. Expert Opinion on Therapeutic Targets, 13(9), 1095-1103. [More Information]
Tan, E., Yan, M., Campo, L., Han, C., Takano, E., Turley, H., Candiloro, I., Pezzela, F., Gatter, K., Millar, E., O'Toole, S., et al (2009). The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. British Journal of Cancer, 100(2), 405-411. [More Information]

show 119 more

By Year

Expand all

2024

Wahi, K., Harvey, K., O'Toole, S., Guan, Y., Holst, J., Freidman, N., Wang, Q., Devadason, M., Quek, L., Pang, A., Larance, M., et al (2024). Macropinocytosis mediates resistance to loss of glutamine transport in triple-negative breast cancer. EMBO Journal, Online(17 October 2024), 1-26. [More Information]

2023

Lambouras, M., Roelofs, C., Pereira, M., Gruber, E., Vieusseux, J., Lanteri, P., Johnstone, C., Muntz, F., O'Toole, S., Ooms, L., et al (2023). Functional and Phenotypic Characterisations of Common Syngeneic Tumour Cell Lines as Estrogen Receptor-Positive Breast Cancer Models. International Journal of Molecular Sciences, 24(6), 5666. [More Information]
McKenzie, C., Karim, R., Kench, J., Klebe, S., Kramer, N., Kumarasinghe, M., Maclean, F., Morey, A., Nguyen, M., O'Toole, S., Gupta, R., Salisbury, E., Scolyer, R., Cooper, W., Anderson, L., Chen, V., et al (2023). Looking beyond workforce parity: addressing gender inequity in pathology. Pathology, 55(6), 760-771. [More Information]
Mulholland, B., Hofstee, P., Millar, E., Bliuc, D., OToole, S., Forwood, M., Mcdonald, M. (2023). MCP-1 expression in breast cancer and its association with distant relapse. Cancer Medicine, 12(15), 16221-16230. [More Information]
Lee, K., Seah, J., O'Toole, S., Warrier, S. (2023). Xanthogranulomatous inflammation and spindle cell proliferation in response to silicone breast implant leakage. BMJ Case Reports, 16(1). [More Information]

show 1 more

2022

Hort, A., O'Toole, S., Yunaev, M. (2022). An unusual case of invasive lobular carcinoma with abundant extracellular mucin. Pathology, 54(1), 138-140. [More Information]
Scolyer, R., Atkinson, V., Gyorki, D., Lambie, D., O'Toole, S., Saw, R., Amanuel, B., Angel, C., Button-Sloan, A., Carlino, M., Ch'ng, S., Daneshvar, D., Esteves Domingues Pires da Silva, I., Ferguson, P., Gill, A., Gupta, R., Hong, A., Howle, J., Jackett, L., Lee, C., et al (2022). BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 54(1), 6-19. [More Information]
Potter, A., Colebatch, A., Rawson, R., Ferguson, P., Cooper, W., Gupta, R., O'Toole, S., Saw, R., Ch'ng, S., Menzies, A., Long, G., Scolyer, R. (2022). Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. Pathology, 54(5), 526-532. [More Information]
Cserni, G., Brogi, E., Cody, H., Deb, R., Farshid, G., OToole, S., Provenzano, E., Quinn, C., Sahin, A., Schmitt, F., et al (2022). Reporting of Surgically Removed Lymph Nodes for Breast Tumors: Recommendations From the International Collaboration on Cancer Reporting. Archives of Pathology & Laboratory Medicine, 146(11), 1308-1318. [More Information]
Fielder, T., Butler, J., Tierney, G., Holmes, M., Lam, K., Satgunaseelan, L., Colebatch, A., Mahar, A., Gupta, R., O'Toole, S., Cooper, W. (2022). ROS1 rearrangements in lung adenocarcinomas are defined by diffuse strong immunohistochemical expression of ROS1. Pathology, 54(4), 399-403. [More Information]
Papanicolaou, M., Parker, A., Yam, M., Filipe, E., Wu, S., Chitty, J., Wyllie, K., Tran, E., Mok, E., Nadalini, A., Oliver, B., Parker, B., et al (2022). Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis. Nature Communications, 13(1). [More Information]

show 3 more

2021

Wu, S., Roden, D., Al-Eryani, G., Bartonicek, N., Harvey, K., Cazet, A., Chan, C., Junankar, S., Hui, M., Millar, E., Horvath, L., Wilmott, J., Quek, C., Long, G., Scolyer, R., et al (2021). Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. Genome Medicine, 13(1), 81. [More Information]
Paver, E., Cooper, W., Colebatch, A., Ferguson, P., Hill, S., Lum, T., Shin, J., O'Toole, S., Anderson, L., Scolyer, R., Gupta, R. (2021). Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology, 53(2), 141-156. [More Information]
Paver, E., O'Toole, S., Cheng, X., Mahar, A., Cooper, W. (2021). Updates in the molecular pathology of non-small cell lung cancer. Seminars in Diagnostic Pathology, 38(5), 54-61. [More Information]

2020

Jankovic-Karasoulos, T., Bianco-Miotto, T., Butler, M., Butler, L., McNeil, C., O’Toole, S., Millar, E., Sakko, A., Ruiz, A., Birrell, S., et al (2020). Elevated levels of tumour apolipoprotein D independently predict poor outcome in breast cancer patients. Histopathology, 76(7), 976-987. [More Information]
Kalaw, E., Lim, M., Kutasovic, J., Sokolova, A., Taege, L., Johnstone, K., Bennett, J., Saunus, J., Niland, C., Ferguson, K., Pathmanathan, N., et al (2020). Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. British Journal of Cancer, 123(11), 1665-1672. [More Information]
Millar, E., Browne, L., Slapetova, I., Shang, F., Ren, Y., Bradshaw, R., Brauer, H., O'Toole, S., Beretov, J., Whan, R., et al (2020). Tils immunophenotype in breast cancer predicts local failure and overall survival: Analysis in a large radiotherapy trial with long-term follow-up. Cancers, 12(9), 1-15. [More Information]

2019

Smith, H., Hirukawa, A., Sanguin-Gendreau, V., Nandi, I., Dufour, C., Zuo, D., Tandoc, K., Leibovitch, M., Singh, S., Rennhack, J., Beith, J., O'Toole, S., et al (2019). An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis. Nature Communications, 10(1), 1-19. [More Information]
Luk, P., Selinger, C., Cooper, W., Mahar, A., Palme, C., O'Toole, S., Clark, J., Gupta, R. (2019). Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms. Head and Neck Pathology, 13(3), 397-414. [More Information]
McCabe, M., Gauthier, M., Chan, C., Thompson, T., De Sousa, S., Puttick, C., Grady, J., Gayevskiy, V., Tao, J., Ying, K., Kohonen-Corish, M., O'Toole, S., Clark, J., Gupta, R., et al (2019). Development and validation of a targeted gene sequencing panel for application to disparate cancers. Scientific Reports, 9(1), 1-16. [More Information]
Heyer, E., Deveson, I., Wooi, D., Selinger, C., Lyons, R., Hayes, V., O'Toole, S., Ballinger, M., Gill, D., Thomas, D., et al (2019). Diagnosis of fusion genes using targeted RNA sequencing. Nature Communications, 10(1), 1-12. [More Information]
Vargas, A., Selinger, C., Satgunaseelan, L., Cooper, W., Gupta, R., Stalley, P., Brown, W., Soper, J., Schatz, J., Boyle, R., Tattersall, M., Bhadri, V., Scolyer, R., Karim, R., McCarthy, S., O'Toole, S., et al (2019). FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center. Asia-Pacific Journal of Clinical Oncology, 15(1), 38-47. [More Information]
Strach, M., Prasanna, T., Kirova, Y., Alran, S., O'Toole, S., Beith, J., Poortmans, P., McNeil, C., Carroll, S. (2019). Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery. Critical Reviews in Oncology / Hematology (online), 134, 10-21. [More Information]
Brockwell, N., Rautela, J., Owen, K., Gearing, L., Deb, S., Harvey, K., Spurling, A., Zanker, D., Chan, C., Cumming, H., O'Toole, S., et al (2019). Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. n p j Precision Oncology, 3(1). [More Information]

show 4 more

2018

Zilberg, C., Lee, M., Yu, B., Ashford, B., Kraitsek, S., Ranson, M., Shannon, K., Cowley, M., Iyer, N., Palme, C., Ch'ng, S., Low, T., O'Toole, S., Clark, J., Gupta, R. (2018). Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma. Modern Pathology, 31(2), 275-287. [More Information]
Duivenvoorden, H., Spurling, A., O'Toole, S., Parker, B. (2018). Discriminating the earliest stages of mammary carcinoma using myoepithelial and proliferative markers. PloS One, 13(7), 1-12. [More Information]
Gupta, R., Cooper, W., Selinger, C., Mahar, A., Anderson, L., Buckland, M., O'Toole, S. (2018). Fluorescent In Situ Hybridization in Surgical Pathology Practice. Advances in Anatomic Pathology, 25(4), 223-237. [More Information]
Rogers, S., McCloy, R., Parker, B., Gallego-Ortega, D., Law, A., Chin, V., Conway, J., Fey, D., Millar, E., O'Toole, S., Cesare, A., James, D., Burgess, A., et al (2018). MASTL overexpression promotes chromosome instability and metastasis in breast cancer. Oncogene, 37(33), 4518-4533. [More Information]
Pajic, M., Froio, D., Daly, S., Doculara, L., Millar, E., Graham, P., Drury, A., Steinmann, A., de Bock, C., O'Toole, S., Gee, H., et al (2018). miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense. Cancer Research, 78(2), 501-515. [More Information]
Cazet, A., Hui, M., Elsworth, B., Wu, S., Roden, D., Chan, C., Skhinas, J., Collot, R., O'Toole, S., et al (2018). Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nature Communications, 9(1), 2897. [More Information]
Ricciardelli, C., Bianco-Miotto, T., Jindal, S., Butler, L., Leung, S., McNeil, C., O'Toole, S., Ebrahimie, E., Millar, E., et al (2018). The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. Clinical Cancer Research, 24(10), 2328-2340. [More Information]
Zardavas, D., te Marvelde, L., Milne, R., Fumagalli, D., Fountzilas, G., Kotoula, V., Razis, E., Papaxoinis, G., Joensuu, H., O’Toole, S., et al (2018). Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. Journal of Clinical Oncology, 36(10), 981-990. [More Information]

show 5 more

2017

Law, A., Yin, J., Castillo, L., Young, A., Piggin, C., Rogers, S., Caldon, C., Burgess, A., Millar, E., O’Toole, S., et al (2017). Andy's Algorithms: New automated digital image analysis pipelines for FIJI. Scientific Reports, 7(1), 1-11. [More Information]
Pang, J., Savas, P., Fellowes, A., Mir Arnau, G., Kader, T., Vedururu, R., Hewitt, C., Takano, E., Byrne, D., Lee, C., O'Toole, S., et al (2017). Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. Modern Pathology, 30(7), 952-963. [More Information]
Barnet, M., O'Toole, S., Horvath, L., Selinger, C., Yu, B., Ng, C., Boyer, M., Cooper, W., Kao, S. (2017). EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 12(3), 585-590. [More Information]
Pang, J., Molania, R., Chand, A., Knower, K., Takano, E., Byrne, D., Mikeska, T., Millar, E., Lee, C., O'Toole, S., et al (2017). LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness. Oncotarget, 8(48), 83626-83636. [More Information]
Harris, G., O'Toole, S., George, P., Browett, P., Print, C. (2017). Massive parallel sequencing of solid tumours - challenges and opportunities for pathologists. Histopathology, 70, 123-133. [More Information]
Duivenvoorden, H., Rautela, J., Edgington-Mitchell, L., Spurling, A., Greening, D., Nowell, C., Molloy, T., Robbins, E., Brockwell, N., Lee, C., O'Toole, S., et al (2017). Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion. Journal of Pathology, 243(4), 496-509. [More Information]
Selinger, C., Li, B., Pavlakis, N., Links, M., Gill, A., Lee, A., Clarke, S., Tran, T., Lum, T., Yip, P., Horvath, L., Yu, B., O'Toole, S., Cooper, W., et al (2017). Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. Histopathology, 70(3), 402-411. [More Information]
Khoo, T., Yu, B., Smith, J., Clarke, A., Luk, P., Selinger, C., Mahon, K., Kraitsek, S., Palme, C., Boyer, M., O'Toole, S., Clark, J., Gupta, R., et al (2017). Somatic mutations in salivary duct carcinoma and potential therapeutic targets. Oncotarget, 8(44), 75893-75903. [More Information]
Coulson, R., Liew, S., Connelly, A., Yee, N., Deb, S., Kumar, B., Vargas, A., O'Toole, S., Parslow, A., Poh, A., et al (2017). The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget, 8(12), 18640-18656. [More Information]

show 6 more

2016

Tran, T., Selinger, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2016). Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases. Clinical Lung Cancer, 17(1), 30-38. [More Information]
van Geldermalsen, M., Wang, Q., Nagarajah, R., Marshall, A., Thoeng, A., Gao, D., Ritchie, W., Feng, Y., Bailey, C., Deng, N., Beith, J., O'Toole, S., Rasko, J., Holst, J., et al (2016). ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene, 35(24), 3201-3208. [More Information]
Vargas, A., Selinger, C., Satgunaseelan, L., Cooper, W., Gupta, R., Stalley, P., Brown, W., Soper, J., Schatz, J., Boyle, R., Tattersall, M., Bhadri, V., Scolyer, R., Karim, R., McCarthy, S., O'Toole, S., et al (2016). Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases. Histopathology, 69(6), 1000-1011. [More Information]
Kakavand, H., Walker, E., Lum, T., Wilmott, J., Selinger, C., Smith, E., Saw, R., Yu, B., Cooper, W., Long, G., O'Toole, S., Scolyer, R. (2016). BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology, 69(4), 680-686. [More Information]
Ryu, S., Ho, K., O'Toole, S., Green, A., Kim, H. (2016). Case report of male breast cancer detected on magnetic resonance imaging. Journal of Medical Imaging and Radiation Oncology, 61(3), 369-371. [More Information]
Luk, P., Wykes, J., Selinger, C., Ekmejian, R., Tay, J., Gao, K., Eviston, T., Lum, T., O'Toole, S., Clark, J., Gupta, R. (2016). Diagnostic and prognostic utility of Mastermind-like 2 (MAML2) gene rearrangement detection by fluorescent in situ hybridization (FISH) in mucoepidermoid carcinoma of the salivary glands. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, 121(5), 530-541. [More Information]
Russell, P., Van Der Griend, R., Anderson, L., Yu, B., O'Toole, S., Simcock, B. (2016). Evidence for lymphatic pathogenesis of endosalpingiosis. Pathology, 48(1), 72-76. [More Information]
Reagh, J., Eckstein, R., Selinger, C., Evans, J., O'Toole, S., Gill, A. (2016). Liposarcoma masquerading as an inflammatory pseudotumor: a case report. Journal of Medical Case Reports, 10(1), 1-3. [More Information]
Young, A., Law, A., Castillo, L., Chong, S., Cullen, H., Koehler, M., Herzog, S., Brummer, T., Lee, E., O'Toole, S., et al (2016). MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib. Breast Cancer Research, 18(1), 1-15. [More Information]
Beckers, R., Selinger, C., Vilain, R., Madore, J., Wilmott, J., Harvey, K., Holliday, A., Cooper, C., Robbins, E., Gillett, D., Kennedy, C., Gluch, L., Carmalt, H., Warrier, S., Gee, H., Chan, C., McLean, A., Walker, E., McNeil, C., Beith, J., Scolyer, R., O'Toole, S., et al (2016). Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology, 69(1), 25-34. [More Information]
Luk, P., Weston, J., Yu, B., Selinger, C., Ekmejian, R., Eviston, T., Lum, T., Gao, K., Boyer, M., O'Toole, S., Clark, J., Gupta, R. (2016). Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations. Head and Neck, 38(Suppl 1), e1838-e1847. [More Information]
Denkert, C., Wienert, S., Poterie, A., Loibl, S., Budczies, J., Badve, S., Bago-Horvath, Z., Bane, A., Bedri, S., O'Toole, S., et al (2016). Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 29(10), 1155-1164. [More Information]
Lyle, M., Haydu, L., Menzies, A., Thompson, J., Saw, R., Spillane, A., Kefford, R., Mann, G., Cooper, W., Yu, B., Scolyer, R., O'Toole, S., Long, G. (2016). The molecular profile of metastatic melanoma in Australia. Pathology, 48(2), 188-193. [More Information]
O'Toole, S. (2016). What do I need to know about somatic mutation testing as a tissue pathologist - A survival guide? Advances in Anatomic Pathology, 48(S1), S9-S10. [More Information]

show 11 more

2015

Chou, A., Fraser, S., Toon, C., Clarkson, A., Sioson, L., Farzin, M., Cussigh, C., Aniss, A., O'Neill, C., Watson, N., Clifton-Bligh, R., Learoyd, D., Robinson, B., Delbridge, L., Sidhu, S., O'Toole, S., Sywak, M., Gill, A., et al (2015). A Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 39(5), 652-659. [More Information]
Luk, P., Yu, B., Ng, C., Mercorella, B., Selinger, C., Lum, T., Kao, S., O'Toole, S., Cooper, W. (2015). BRAF mutations in non-small cell lung cancer. Translational Lung Cancer Research, 4(2), 142-148. [More Information]
Loh, S., Cooper, C., Selinger, C., Barnes, E., Chan, C., Carmalt, H., West, R., Gluch, L., Beith, J., Caldon, C., O'Toole, S. (2015). Cell cycle marker expression in benign and malignant intraductal papillary lesions of the breast. Journal of Clinical Pathology, 68(3), 187-191. [More Information]
Gallego-Ortega, D., Ledger, A., Roden, D., Law, A., Magenau, A., Kikhtyak, Z., Cho, C., Allerdice, S., Lee, H., Valdes-Mora, F., Naylor, M., O'Toole, S., et al (2015). ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells. PLoS Biology, 13(12), 1-27. [More Information]
Li, B., Lee, A., O'Toole, S., Cooper, W., Yu, B., Chaft, J., Arcila, M., Kris, M., Pavlakis, N. (2015). HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. Lung Cancer, 90(3), 617-619. [More Information]
Junankar, S., Baker, L., Roden, D., Nair, R., Elsworh, B., Gallego-Ortega, D., Lacaze, P., Cazet, A., Nikolic, I., Teo, W., Naylor, M., O'Toole, S., et al (2015). ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype. Nature Communications, 6, 1-12. [More Information]
Luk, P., Selinger, C., Eviston, T., Lum, T., Yu, B., O'Toole, S., Clark, J., Gupta, R. (2015). Mammary analogue secretory carcinoma: an evaluation of its clinicopathological and genetic characteristics. Pathology, 47(7), 659-666. [More Information]
Phua, Y., Nguyen, A., Roden, D., Elsworth, B., Deng, N., Nikolic, I., Yang, J., McFarland, A., Russell, R., Kaplan, W., O'Toole, S., James, D., et al (2015). MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene. Breast Cancer Research, 17(1), 1-18. [More Information]
Gee, H., Buffa, F., Harris, A., Toohey, J., Carroll, S., Cooper, C., Beith, J., McNeil, C., Carmalt, H., Mak, C., Kennedy, C., O'Toole, S., et al (2015). MicroRNA-Related DNA repair/ cell-cycle genes independently associated with relapse after radiation therapy for early breast cancer. International Journal of Radiation Oncology Biology Physics, 93(5), 1104-1114. [More Information]
Cooper, W., Tran, T., Vilain, R., Madore, J., Selinger, C., Kohonen-Corish, M., Yip, P., Yu, B., O'Toole, S., McCaughan, B., Horvath, L., Kao, S., Boyer, M., Scolyer, R., et al (2015). PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer, 89(2), 181-188. [More Information]
Warrier, S., Hwang, S., Gibbings, K., Carmalt, H., O'Toole, S. (2015). Phyllodes tumour with heterologous sarcomatous differentiation: Case series with literature review. International Journal of Surgery Case Reports, 11, 91-94. [More Information]
Yu, B., O'Toole, S., Trent, R. (2015). Somatic DNA mutation analysis in targeted therapy of solid tumours. Translational Pediatrics, 4(2), 125-138. [More Information]
Wang, S., Yu, B., Ng, C., Mercorella, B., Selinger, C., O'Toole, S., Cooper, W. (2015). The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. Translational Lung Cancer Research, 4(2), 119-125. [More Information]

show 10 more

2014

Gibbings, K., Warrier, S., Hwang, S., Rice, M., O'Toole, S., Carmalt, H. (2014). A giant phyllodes tumour with sepsis. ANZ Journal of Surgery, 84(11), 886-887. [More Information]
Tran, T., Selinger, C., Yu, B., Ng, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2014). Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer. Journal of Clinical Pathology, 67(11), 985-991. [More Information]
Nair, R., Roden, D., Teo, W., McFarland, A., Junankar, S., Ye, S., Nguyen, A., Yang, J., Nicolic, I., Hui, M., Armstrong, N., Naylor, M., O'Toole, S., et al (2014). c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene, 33(30), 3992-4002. [More Information]
Kakavand, H., Crainic, O., Lum, T., O'Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193-198. [More Information]
Carlino, M., Haydu, L., Kakavand, H., Menzies, A., Hamilton, A., Yu, B., Ng, C., Cooper, W., Thompson, J., Kefford, R., O'Toole, S., Scolyer, R., Long, G. (2014). Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 111(2), 292-299. [More Information]
Houang, M., Sioson, L., Clarkson, A., Watson, N., Mahtab, F., Toon, C., Raut, A., O'Toole, S., Cooper, W., Pavlakis, N., Gill, A., et al (2014). EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology, 46(6), 501-508. [More Information]
Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
Pang, J., Deb, S., Takano, E., Byrne, D., Jene, N., Boulghourjian, A., Holliday, A., Millar, E., Lee, C., O'Toole, S., et al (2014). Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features. Breast Cancer Research, 16(1), 1-11. [More Information]
O'Toole, S., Yu, B., Cooper, W. (2014). Molecular Diagnosis in Cytology and Its Place in the New Classification: A Practical Guide. The Journal of OncoPathology, 2(1), 63-73. [More Information]
Cooper, W., Fox, S., O'Toole, S., Morey, A., Frances, G., Pavlakis, N., O'Brien, K., Dettrick, A., Leong, T., Rathi, V., et al (2014). National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 10(S 2), 11-17. [More Information]
Houang, M., Toon, C., Clarkson, A., Sioson, L., Watson, N., Farzin, M., Selinger, C., Chou, A., Morey, A., Cooper, W., O'Toole, S., Gill, A. (2014). Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer. Pathology, 46(5), 383-388. [More Information]
Nguyen, N., Hampartzoumian, T., Cameron, B., Palmer, C., O'Toole, S., Post, J., Zekry, A., Lloyd, A. (2014). Regulation of T cell recruitment and inflammation in the human immunodeficiency virus/hepatitis C virus coinfected liver. Journal of Gastroenterology and Hepatology, 29(7), 1535-1543. [More Information]

show 9 more

2013

Schade, B., Lesurf, R., Sanguin-Gendreau, V., Bui, T., Deblois, G., O'Toole, S., Millar, E., Zardawi, S., Lopez-Knowles, E., Sutherland, R., et al (2013). B-Catenin Signaling is a Critical Event in ErbB2-Mediated Mammary Tumor Progression. Cancer Research, 73(14), 4474-4487. [More Information]
Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma. European Journal of Cancer, 49(5), 1073-1079. [More Information]
Klein, O., Clements, A., Menzies, A., O'Toole, S., Kefford, R., Long, G. (2013). BRAF inhibitor activity in V600R metastatic melanoma â€“ Response. European Journal of Cancer, 49(7), 1797-1798. [More Information]
O'Toole, S., Rakha, E., Ellis, I., Tan, P. (2013). Breast pathology today: morphology and molecules. Journal of Clinical Pathology, 66(6), 457. [More Information]
Cooper, C., O'Toole, S., Kench, J. (2013). Classification, morphology and molecular pathology of premalignant lesions of the pancreas. Pathology, 45(3), 286-304. [More Information]
Cooper, W., Yu, B., Yip, P., Ng, C., Lum, T., Farzin, M., Trent, R., Mercorella, B., Clarkson, A., Kohonen-Corish, M., Horvath, L., Kench, J., McCaughan, B., Gill, A., O'Toole, S. (2013). EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. Journal of Clinical Pathology, 66(9), 744-748. [More Information]
Tran, T., Selinger, C., Kohonen-Corish, M., McCaughan, B., Kennedy, C., O'Toole, S., Cooper, W. (2013). Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer, 81(3), 462-467. [More Information]
Browne, B., Hochgrafe, F., Wu, J., Millar, E., Barraclough, J., Stone, A., McCloy, R., Lee, C., Roberts, C., Ali, N., O'Toole, S., et al (2013). Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. FEBS Journal, 280(21), 5237-5257. [More Information]
Cooper, C., Karim, R., Selinger, C., Carmalt, H., Lee, C., O'Toole, S. (2013). Molecular alterations in metaplastic breast carcinoma. Journal of Clinical Pathology, 66(6), 522-528. [More Information]
Cooper, W., Lam, D., O'Toole, S., Minna, J. (2013). Molecular biology of lung cancer. Journal of Thoracic Disease, 5(S5), S479-S490. [More Information]
Cooper, W., O'Toole, S. (2013). Molecular Pathology in lung Cancer. Cancer Forum, 37(2), 1-7.
Yip, P., Yu, B., Cooper, W., Selinger, C., Ng, C., Kennedy, C., Kohonen-Corish, M., McCaughan, B., Trent, R., Boyer, M., Kench, J., Horvath, L., O'Toole, S. (2013). Patterns of DNA mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology, 8(4), 408-414. [More Information]
Saunderson, R., Garsia, R., Headley, A., McCaughan, G., O'Toole, S., Strasser, S. (2013). Pentoxifylline-induced drug rash with eosinophilia and systemic symptoms (DRESS) in a patient with caffeine intolerance. Journal of Dermatological Case Reports, 7(3), 77-81. [More Information]
Karim, R., O'Toole, S., Scolyer, R., Cooper, C., Chan, B., Selinger, C., Yu, B., Carmalt, H., Mak, C., Tse, G., Lee, C., et al (2013). Recent insights into the molecular pathogenesis of mammary phyllodes tumours. Journal of Clinical Pathology, 66(6), 496-505. [More Information]
Shields, B., Wiede, F., Gurzov, E., Wee, K., Hauser, C., Zhu, H., Molloy, T., O'Toole, S., Daly, R., Sutherland, R., et al (2013). TCPTP Regulates SFK and STAT3 Signaling and Is Lost in Triple-Negative Breast Cancers. Molecular and Cellular Biology, 33(3), 557-570. [More Information]
Selinger, C., Rogers, T., Russell, P., O'Toole, S., Yip, P., Wright, G., Wainer, Z., Horvath, L., Boyer, M., McCaughan, B., et al (2013). Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology, 26(12), 1545-1553. [More Information]
Hui, M., Cazet, A., Nair, R., Watkins, D., O'Toole, S., Swarbrick, A. (2013). The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Research, 15(2), 1-14. [More Information]
O'Toole, S., Beith, J., Millar, E., West, R., McLean, A., Cazet, A., Swarbrick, A., Oakes, S. (2013). Therapeutic targets in triple negative breast cancer. Journal of Clinical Pathology, 66(6), 530-542. [More Information]

show 15 more

2012

Coates, A., Millar, E., O'Toole, S., Molloy, T., Viale, G., Goldhirsch, A., Regan, M., Gelber, R., Sun, Z., Castiglione-Gertsch, M., et al (2012). Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Research, 14(6), 1-12. [More Information]

2011

Xu, H., Yan, M., Patra, J., Natrajan, R., Yan, Y., Swagemakers, S., Tomaszewski, J., Verschoor, S., Millar, E., van der Spek, P., O'Toole, S., McNeil, C., et al (2011). Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Research, 13(1), R9-1-R9-36. [More Information]
O'Toole, S., Machalek, D., Shearer, R., Millar, E., Nair, R., Schofield, P., McLeod, D., Cooper, C., McNeil, C., McFarland, A., et al (2011). Hedgehog Overexpression Is Associated with Stromal Interactions and Predicts for Poor Outcome in Breast Cancer. Cancer Research, 71(11), 4002-4014. [More Information]
Roberts, C., Millar, E., O'Toole, S., McNeil, C., Lehrbach, G., Pinese, M., Tobelmann, P., McCloy, R., Musgrove, E., Sutherland, R., et al (2011). Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene, 30(28), 3186-3197. [More Information]
O'Toole, S., Selinger, C., Millar, E., Lum, T., Beith, J. (2011). Molecular assays in breast cancer pathology. Pathology, 43(2), 116-127. [More Information]
Millar, E., Graham, P., McNeil, C., Browne, L., O'Toole, S., Boulghourjian, A., Kearsley, J., Papadatos, G., Delaney, G., Fox, C., et al (2011). Prediction of outcome of early ER + breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. British Journal of Cancer, 105(2), 272-280. [More Information]
Colvin, E., Susanto, J., Kench, J., Ong, V., Mawson, A., Pinese, M., Chang, D., Rooman, I., O'Toole, S., Segara, D., et al (2011). Retinoid signaling in pancreatic cancer, injury and regeneration. PloS One, 6(12), e29075 - 1-e29075 - 10. [More Information]
Chan, P., MÃ¶ller, A., Liu, M., Sceneay, J., Wong, C., Waddell, N., Huang, K., Dobrovic, A., Millar, E., O'Toole, S., et al (2011). The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. Breast Cancer Research, 13(1), 1-10. [More Information]
Cooper, W., O'Toole, S., Boyer, M., Horvath, L., Mahar, A. (2011). What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 43(2), 103-115. [More Information]

show 5 more

2010

Lopez-Knowles, E., Zardawi, S., McNeil, C., Millar, E., Crea, P., Musgrove, E., Sutherland, R., O'Toole, S. (2010). Cytoplasmic Localization of beta-Catenin is a Marker of Poor Outcome in Breast Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 19(1), 301-309. [More Information]
Zardawi, S., Zardawi, I., McNeil, C., Millar, E., McLeod, D., Morey, A., Crea, P., Murphy, N., Pinese, M., Lopez-Knowles, E., Hamilton, A., Spillane, A., Lee, C., et al (2010). High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology, 56(3), 286-296. [More Information]
Murphy, N., Biankin, A., Millar, E., McNeil, C., O'Toole, S., Segara, D., Crea, P., Olayioye, M., Lee, C., Fox, S., et al (2010). Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. International Journal of Cancer, 126(6), 1445-1453. [More Information]
Fleuren, E., O'Toole, S., Millar, E., McNeil, C., Lopez-Knowles, E., Boulghourjian, A., Croucher, D., Schramek, D., Brummer, T., Penninger, J., et al (2010). Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development. International Journal of Cancer, 127(6), 1486-92. [More Information]
Lopez-Knowles, E., O'Toole, S., McNeil, C., Millar, E., Qiu, M., Crea, P., Daly, R., Musgrove, E., Sutherland, R. (2010). PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. International Journal of Cancer, 126(5), 1121-1131. [More Information]
Nair, R., Junankar, S., O'Toole, S., Shah, J., Borowsky, A., Bishop, J., Swarbrick, A. (2010). Redefining the expression and function of the inhibitor of differentiation 1 in mammary gland development. PloS One, 5(8), 1-7. [More Information]
Palmer, C., Corpuz, T., Marianne, G., O'Toole, S., Yan, K., Bu, Y., Jorgenson, J., Talbot, M., Loi, K., Lloyd, A., et al (2010). The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis c infection. Gut, 59(3), 397-404. [More Information]
Hochgrafe, F., Zhang, L., O'Toole, S., Browne, B., Pinese, M., Cubas, A., Lehrbach, G., Lehrbach, D., Rickwood, D., Boulghourjian, A. (2010). Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells. Cancer Research, 70(22), 9391-9401. [More Information]

show 5 more

2009

Millar, E., Anderson, L., McNeil, C., O'Toole, S., Pinese, M., Crea, P., Morey, A., Biankin, A., Henshall, S., Musgrove, E., et al (2009). BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. British Journal of Cancer, 100(1), 123-133. [More Information]
Millar, E., Dean, J., McNeil, C., O'Toole, S., Henshall, S., Lin, J., Quong, A., Comstock, C., Witkiewicz, A., Musgrove, E., et al (2009). Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene, 28(15), 1812-1820. [More Information]
Zhang, J., O'Toole, S., Sutherland, R., Musgrove, E. (2009). Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histology and histopathology, 24(3), 385-398. [More Information]
Kitzing, B., O'Toole, S., Waugh, A., Clayton, J., McGill, N., Allman, K. (2009). Hepatobiliary scintigraphy in vasculitis of the gallbladder as a manifestation of polyarteritis nodosa: a case report. Cases Journal, 2, 9300. [More Information]
Millar, E., Graham, P., O'Toole, S., McNeil, C., Browne, L., Morey, A., Eggleton, S., Beretov, J., Theocharous, C., Capp, A. (2009). Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. Journal of Clinical Oncology, 27(28), 4701-4708. [More Information]
O'Toole, S., Swarbrick, A., Sutherland, R. (2009). The Hedgehog signalling pathway as a therapeutic target in early breast cancer development. Expert Opinion on Therapeutic Targets, 13(9), 1095-1103. [More Information]
Tan, E., Yan, M., Campo, L., Han, C., Takano, E., Turley, H., Candiloro, I., Pezzela, F., Gatter, K., Millar, E., O'Toole, S., et al (2009). The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. British Journal of Cancer, 100(2), 405-411. [More Information]

show 4 more

Selected Grants

2024

FMH Start-up Scheme, O'Toole S, Faculty of Medicine and Health/New Academic Staff Funding

2017

Targeting glutamine addiction of triple-negative breast cancer TNBC, Holst J, Swarbrick A, O'Toole S, Beith J, Cancer Council NSW/Research Grant
The Sydney University Immunotherapy Hub: Improving the efficacy of Immunotherapy, Palendira M, Britton W, Scolyer R, Long G, O'Toole S, Hersey P, DVC Research/Sydney Research Excellence Initiative 2020 (SREI)

Page not found

Professor Sandra O'Toole

Publications

By Type

By Year

Selected Grants

2024

2017